List of Excipients in Branded Drug KERENDIA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bayer HealthCare Pharmaceuticals Inc	KERENDIA	finerenone	50419-540	CELLULOSE, MICROCRYSTALLINE	2035-07-29
Bayer HealthCare Pharmaceuticals Inc	KERENDIA	finerenone	50419-540	CROSCARMELLOSE SODIUM	2035-07-29
Bayer HealthCare Pharmaceuticals Inc	KERENDIA	finerenone	50419-540	HYPROMELLOSE	2035-07-29
Bayer HealthCare Pharmaceuticals Inc	KERENDIA	finerenone	50419-540	LACTOSE MONOHYDRATE	2035-07-29

Kerendia Excipient Strategy and Commercial Opportunities for Finerenone

Last updated: September 9, 2026

Kerendia, Bayer’s finerenone product, is an immediate-release, film-coated oral tablet approved by the FDA for adults with chronic kidney disease associated with type 2 diabetes. Its commercial formulation uses conventional, widely available excipients rather than a proprietary delivery platform. The main opportunities are therefore in generic substitution, cost reduction, differentiated excipient systems, lactose-free products, manufacturing efficiency and regional formulation adaptation.

Kerendia is supplied in two strengths:

Strength	Tablet color	Active ingredient	Dosage form
10 mg	Pink	Finerenone	Film-coated tablet
20 mg	Yellow	Finerenone	Film-coated tablet

The labeled inactive ingredients are croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate and talc. The film coating contains hypromellose, talc, titanium dioxide and ferric oxide colorants. The 10 mg and 20 mg tablets use different iron oxide color systems for strength identification. [1]

What excipients are used in Kerendia tablets?

Kerendia uses a standard wet- or dry-granulation-compatible tablet platform built around a filler, disintegrant, lubricant, surfactant and coating system.

Excipient	Likely functional role	Commercial relevance
Lactose monohydrate	Diluent and compression aid	Low-cost, globally available; creates lactose-intolerance and supply-chain considerations
Microcrystalline cellulose	Diluent, dry binder and compression aid	Supports tablet hardness and manufacturability
Croscarmellose sodium	Superdisintegrant	Controls tablet breakup and can affect dissolution
Sodium lauryl sulfate	Wetting agent and surfactant	May improve wetting of poorly soluble drug particles; can create tolerability and labeling considerations
Magnesium stearate	Lubricant	Required for ejection and tooling protection; over-lubrication can slow dissolution
Talc	Processing aid and coating component	Supports coating performance and reduces tack
Hypromellose	Film-forming polymer	Standard immediate-release coating polymer
Titanium dioxide	Opacifier and whitening agent	Regulatory restrictions differ by market
Ferric oxide pigments	Tablet-color identification	Supports dose differentiation and product recognition

The formulation does not indicate an extended-release system, enteric coating, osmotic delivery system or lipid-based dispersion. FDA labeling states that Kerendia can be taken with or without food, reducing the commercial need for a food-effect-mitigating delivery system. [1]

How does finerenone’s drug substance affect excipient selection?

Finerenone is a nonsteroidal mineralocorticoid receptor antagonist with low aqueous solubility. For an immediate-release product, excipient selection must support rapid wetting, disintegration and reproducible dissolution across the gastrointestinal pH range.

Sodium lauryl sulfate is the most strategically significant excipient in the reference formulation because it can improve powder wetting and help reduce dissolution variability. Croscarmellose sodium and microcrystalline cellulose provide the disintegration and compactability framework. Magnesium stearate concentration and blending time require tight control because excessive hydrophobic lubrication can reduce liquid penetration and delay drug release.

A generic developer should characterize:

• Particle-size distribution and crystal form of finerenone.
• Drug loading and content uniformity at the 10 mg strength.
• Tablet tensile strength and friability.
• Disintegration time after accelerated stability storage.
• Dissolution across relevant pH conditions.
• Surfactant sensitivity and magnesium-stearate lubrication effects.
• Compatibility with lactose, cellulose, pigments and coating polymers.
• Impact of manufacturing scale on blend uniformity and dissolution.

The reference formulation provides a practical starting point, but an ANDA applicant does not necessarily need to duplicate every inactive ingredient. FDA permits differences in excipients when the product meets applicable pharmaceutical-equivalence, bioequivalence, quality and labeling requirements. [2]

What formulation patents protect Kerendia?

The key intellectual-property risk for a finerenone generic is likely to center on the active ingredient, pharmaceutical compositions, therapeutic uses and regulatory exclusivity rather than on commodity excipients alone.

Publicly available FDA and patent records should be reviewed for:

1. Finerenone composition-of-matter patents.
2. Pharmaceutical-composition patents covering tablet formulations.
3. Method-of-use patents for diabetic kidney disease and related cardiovascular or renal indications.
4. Polymorph, salt, crystalline-form or particle-size claims.
5. Manufacturing-process patents.
6. Pediatric exclusivity and patent-term-extension records.
7. Orange Book-listed patents and associated expiration dates.

The Kerendia label identifies Bayer as the applicant and sponsor. The FDA Orange Book remains the controlling source for currently listed patents, use codes and pediatric exclusivity. [3] Patent numbers and expiration dates should not be inferred from third-party product databases because Orange Book listings can change through delisting, corrections, patent-term adjustments or litigation settlements.

Are Kerendia’s excipients themselves strongly protected?

The individual excipients in the reference product are established, off-patent materials. Lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, sodium lauryl sulfate, hypromellose, talc and common iron oxides are supplied by multiple manufacturers.

The more credible IP exposure lies in the combination, process or performance specification. A patent could attempt to claim:

• A particular finerenone particle-size range.
• A defined surfactant-to-drug ratio.
• A specific dissolution profile.
• A manufacturing sequence.
• A coating composition.
• A formulation with improved stability or bioavailability.
• A method of treating a defined renal or cardiovascular population.

A generic applicant using the same conventional excipients can still face risk if its formulation practices fall within a valid composition or process claim.

When does Kerendia lose exclusivity?

Kerendia received FDA approval on July 9, 2021. As a new chemical entity, finerenone received five years of FDA exclusivity, subject to the statutory rules governing ANDA submission and approval. The five-year NCE period points to July 9, 2026, before accounting for any pediatric exclusivity or other regulatory effects. [1,4]

Exclusivity element	Kerendia position
FDA approval	July 9, 2021
NCE exclusivity	Generally five years from approval
Earliest ordinary ANDA filing period	Typically after four years, subject to applicable patent and regulatory conditions
Approximate NCE exclusivity endpoint	July 9, 2026
Patent-based launch date	Depends on Orange Book patents, litigation and settlement terms
Biosimilar pathway	Not applicable; finerenone is a small molecule

Patent protection may extend beyond the NCE period. The commercial launch date for a generic depends on the latest enforceable patent, any 30-month stay from Paragraph IV litigation, court decisions, settlement terms and the applicant’s ability to secure tentative or final approval.

What Paragraph IV challenges and generic entry risks exist?

A Paragraph IV applicant would assert that a listed patent is invalid, unenforceable or not infringed. The first applicant to submit a substantially complete ANDA with a qualifying Paragraph IV certification may obtain 180 days of generic exclusivity, subject to statutory forfeiture rules and the details of competing filings. [2]

Potential launch scenarios include:

Scenario	Commercial effect
No ANDA filed before NCE expiry	Generic entry starts after regulatory exclusivity ends, subject to patents
Paragraph IV filing without immediate litigation	FDA approval may remain constrained by the listed patent framework
Patent litigation within 45 days	A potential 30-month approval stay may apply
Early settlement	Entry date may be earlier than patent expiry but later than NCE expiry
Successful invalidity or non-infringement ruling	Earlier generic launch becomes possible
At-risk launch	Generic enters before final patent resolution and accepts infringement exposure

For investors and licensing teams, the critical diligence issue is not the existence of a conventional excipient system. It is the interaction between the active-ingredient patent estate, use patents and the timing of any ANDA challenge.

What commercial opportunities exist in Kerendia excipients?

1. Cost-optimized generic formulations

The reference excipient system is commercially attractive because it uses globally established materials. A manufacturer can pursue a low-cost formulation with lactose, microcrystalline cellulose and croscarmellose sodium while preserving rapid disintegration and tablet robustness.

The main savings opportunities are:

• Lower-cost regional excipient sourcing.
• Reduced coating weight.
• Direct compression if blend flow and content uniformity are acceptable.
• Optimized magnesium stearate concentration.
• Reduced processing time through continuous blending or tableting.
• Common excipient platforms across both strengths.

2. Lactose-free formulations

A lactose-free version could replace lactose monohydrate with mannitol, anhydrous dibasic calcium phosphate, silicified microcrystalline cellulose or a co-processed cellulose-based diluent. The formulation must maintain:

• Comparable dissolution.
• Adequate tablet hardness.
• Low friability.
• Stable content uniformity.
• Acceptable tablet size.
• Bioequivalence to Kerendia.

Lactose-free positioning is more commercially relevant in markets with strong excipient-preference claims, hospital procurement requirements or patients who avoid lactose. It is unlikely to support premium pricing by itself in a commodity generic market unless combined with a differentiated channel or supply agreement.

3. Low-surfactant or surfactant-free products

Sodium lauryl sulfate may create opportunities for a gentler formulation using poloxamer, sodium stearyl fumarate, a different wetting system or particle-engineering approach. This could be useful where manufacturers seek to reduce surfactant content or avoid a particular excipient.

The risk is dissolution performance. Removing sodium lauryl sulfate without improving finerenone particle wetting can produce slower or more variable release. A surfactant-free product therefore has technical value only if it retains robust dissolution across pH conditions.

4. Improved tablet identification

Kerendia uses different colors for 10 mg and 20 mg tablets. A generic manufacturer could preserve color differentiation or use an alternative imprint strategy. Opportunity exists in:

• High-contrast imprints for older adults.
• Reduced reliance on titanium dioxide where required by local regulation.
• Visually distinct but stable iron oxide systems.
• Packaging and tablet design that reduce strength-selection errors.

Color changes require careful regulatory assessment because appearance is part of product identification and may affect medication-error risk.

5. Regional excipient compliance

Excipient rules differ across jurisdictions. Titanium dioxide, sodium lauryl sulfate, lactose, talc and colorants may receive different regulatory treatment or customer scrutiny by market. A global product platform should use modular coating and filler systems that can be adapted without changing the active core.

Potential regional strategies include:

• Titanium-dioxide-free coating.
• Lactose-free formulation.
• Alternative colorant system.
• Country-specific excipient declarations.
• Separate manufacturing specifications for markets with different impurity limits.

What manufacturing and IP barriers affect Kerendia generic development?

The primary technical barrier is not tablet manufacture. It is proving consistent performance with a low-dose drug substance and potentially sensitive dissolution behavior.

At 10 mg, finerenone represents a relatively small portion of total tablet mass. That increases the importance of geometric dilution, blend segregation control and assay uniformity. The 20 mg strength may allow greater flexibility in formulation scaling, but proportional composition does not guarantee equivalent dissolution.

Manufacturers should protect process know-how around:

• Drug-excipient premixing.
• Milling and deagglomeration.
• Granulation endpoint.
• Lubrication time.
• Compression force.
• Coating weight gain.
• In-process dissolution controls.
• Stability-indicating analytical methods.

Process patents may be more difficult to design around than formulation patents if they claim broad manufacturing steps or critical material attributes. A non-infringing formulation can still require a distinct process route.

How does Kerendia compare with competing kidney-disease drugs?

Finerenone competes with mineralocorticoid receptor antagonists and broader chronic kidney disease therapies, including spironolactone, eplerenone, sodium-glucose cotransporter-2 inhibitors and renin-angiotensin system therapies.

Product class	Excipient opportunity	Generic or biosimilar pathway	Key commercial issue
Finerenone tablets	Conventional immediate-release optimization	ANDA	Timing of NCE and patent expiry
Spironolactone tablets	Broad low-cost generic sourcing	ANDA	Intense price competition
Eplerenone tablets	Conventional tablet substitution	ANDA	Existing generic competition
SGLT2 inhibitor tablets	Formulation and combination-product opportunities	ANDA after relevant exclusivity	Larger chronic-use markets
Biologic kidney therapies	Complex formulation and device systems	Biosimilar or interchangeable pathway	Higher manufacturing barriers

Finerenone has a more focused clinical positioning than older steroidal mineralocorticoid receptor antagonists. Its commercial value depends on renal and cardiovascular outcome data, guideline adoption, payer coverage and the expansion of eligible patients. A generic developer should model both price erosion and market growth rather than assume that entry will produce immediate high-volume substitution.

What is the FDA regulatory status of Kerendia?

Kerendia is FDA-approved as an oral tablet for adults with chronic kidney disease associated with type 2 diabetes. The FDA-approved strengths are 10 mg and 20 mg. The label includes renal-function and potassium-related dosing considerations, which make product quality and dose identity commercially important. [1]

Because finerenone is a small molecule, biosimilar approval is not relevant. Competing products would ordinarily use the ANDA pathway if they meet the requirements for pharmaceutical equivalence and bioequivalence. A 505(b)(2) pathway could be relevant for a materially different dosage form, route or formulation, but a conventional immediate-release tablet is more naturally aligned with ANDA development.

Key Takeaways

• Kerendia uses a conventional immediate-release film-coated tablet formulation.
• The core excipients are lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, sodium lauryl sulfate and talc.
• Sodium lauryl sulfate is the most formulation-sensitive excipient because finerenone dissolution may depend on effective wetting.
• Lactose-free, low-surfactant, titanium-dioxide-free and cost-optimized formulations offer the clearest commercial opportunities.
• The principal IP risk is likely to involve finerenone composition, use, formulation and process patents rather than ownership of commodity excipients.
• Kerendia’s five-year NCE exclusivity period points to July 9, 2026, while actual generic launch timing depends on Orange Book patents and litigation.
• Finerenone is a small molecule, so generic competition follows the ANDA pathway rather than a biosimilar pathway.
• Low-dose content uniformity, dissolution control and strength differentiation are the central technical requirements for a generic product.

FAQs

Can a generic finerenone tablet use different excipients from Kerendia?

Yes. An ANDA applicant can generally use different inactive ingredients if the product satisfies FDA requirements for pharmaceutical equivalence, bioequivalence, quality, safety and labeling.

Is sodium lauryl sulfate essential in a finerenone formulation?

Not necessarily, but it may be important for wetting and dissolution. A surfactant-free formulation would require comparative dissolution and bioequivalence development.

Is a lactose-free Kerendia alternative commercially attractive?

It can be attractive for selected markets and procurement channels, but lactose removal alone is unlikely to support a durable premium without a clear clinical, tolerability or supply-chain advantage.

Can excipient suppliers license Kerendia formulation technology?

Potentially. The strongest licensing opportunities would involve co-processed excipients, particle-wetting systems, coating platforms, continuous manufacturing or validated dissolution-control technology rather than ordinary commodity materials.

Will Kerendia have biosimilar competition?

No. Finerenone is a chemically synthesized small molecule. Competing products would generally be developed as generics under the ANDA pathway, not as biosimilars.

References

1. U.S. Food and Drug Administration. (2021). Kerendia (finerenone) prescribing information. Bayer HealthCare Pharmaceuticals Inc.

2. U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA) process and generic drug approval standards. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024). New chemical entity exclusivity and generic drug submission requirements. FDA.